About MyovantMyovant Sciences is focused on innovative treatments for women's health conditions and prostate cancer. The company's lead program is relugolix, a phase 3 drug candidate for multiple indications, including uterine fibroids, endometriosis and prostate cancer. Myovant was formed through a strategic partnership between Roivant Sciences and Takeda.
CEO: Lynn Seely
CFO: Frank Karbe
Please click here for Myovant Sciences job opportunities.
Please click here for clinical trial information.
35 articles with Myovant
Here's a roundup of some of the top clinical trial news from the previous week.
Myovant Sciences announced positive data from LIBERTY 1, one of its two Phase III trials of once daily relugolix combination therapy in uterine fibroids. The trial met its primary endpoint and six key secondary endpoints.
Myovant Sciences announced that Lynn Seely, M.D., President and Chief Executive Officer, will present at the following investor conferences:
Myovant Sciences today announced its participation in the following upcoming investor conferences
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
Myovant Provides Corporate Updates and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2018
Completed Patient Enrollment in Phase 3 LIBERTY 1 and HERO Trials
Kim Sablich, Chief Commercial Officer, and Jeff Nornhold, Senior Vice President, Pharmaceutical Operations & Development, join Myovant's Executive Committee
Myovant Sciences and Flo Health Partner to Develop Digital Tool to Screen Women for Heavy Menstrual Bleeding
Collaboration will focus initially on creating a feature in the Flo app to both enable women to monitor for heavy menstrual bleeding and enable research on digital biomarkers for heavy menstrual bleeding
Myovant Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2018
Completed patient screening for Phase 3 LIBERTY 1 Trial
Myovant Sciences Ltd. announced the pricing of its underwritten public offering of 3,333,334 of its common shares at a price to the public of $22.50 per share.
Myovant Sciences Ltd. announced that it has commenced an underwritten public offering of $75 million of its common shares.
Myovant Sciences Announces Completion of Screening for Phase 3 LIBERTY 1 Study Evaluating Relugolix in Women with Uterine Fibroids
Top-line data for LIBERTY 1 expected in second quarter of 2019
Myovant Sciences announced that Lynn Seely, M.D., President and Chief Executive Officer of Myovant Sciences, will present at the first annual Roivant Pipeline Day on July 10, 2018 at 2:30 p.m. ET.
Myovant Provides Corporate Update and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2018
Myovant Sciences announced corporate updates and reported financial results for the fourth fiscal quarter and full fiscal year ended March 31, 2018.
Not only does the company have to deal with the U.S. Food and Drug Administration’s three month PDUFA delay for elagolix, but now the watchdog organization, The Institute for Clinical and Economic Review (ICER), has released some disconcerting news over pricing.
AbbVie and Neurocrine Biosciences announced that its Phase III ELARIS UF-II trial of elagolix for uterine fibroids met its primary endpoint.
Myovant Sciences Provides Corporate Update and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2017
Positive results in two Phase 3 clinical studies conducted by Takeda to evaluate the efficacy and safety of relugolix for the treatment of uterine fibroids.
12/20/2017We now turn to six MoneyShow.com contributors for their best ideas in biotechnology, a sector with both high risk and the potential for high rewards.
Myovant Sciences Provides Corporate Update and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2017
R&D expenses for the quarter ended September 30, 2017 were$24.4M, compared to $3.8M for the comparable period in 2016.
Myovant Sciences Announces Positive Top-line Results From Takeda's Phase III Study Evaluating the Efficacy and Safety of Relugolix for the Treatment of Pain Associated With Uterine Fibroids
Relugolix met the primary endpoint with 57.6% of women achieving marked improvement in pain symptoms compared to 3.1% of women receiving placebo.